

**Investor Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
240-631-3280  
BurrowsR@ebsi.com

**Media Contact:**

Tracey Schmitt Lintott  
Senior Vice President, Global Public Affairs  
240-631-3394  
SchmittT@ebsi.com

**EMERGENT BIOSOLUTIONS TO RELEASE THIRD QUARTER 2016 FINANCIAL RESULTS  
AND CONDUCT A CONFERENCE CALL ON NOVEMBER 7, 2016**

**GAITHERSBURG, MD, October 31, 2016**—Emergent BioSolutions Inc. (NYSE: EBS) will release its financial results for the third quarter on Monday, November 7, 2016 and host a conference call at 5:00 pm (Eastern Time). In the press release and on the conference call, the Company will discuss its financial results for the quarter and year-to-date periods of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.

This conference call can be accessed live by telephone or via webcast:

**Live Teleconference Information:**

Dial in number: **(855) 766-6521**  
*International dial in: (262) 912-6157*  
Conference ID: **29486767**

**Live Webcast Information:**

Visit <http://edge.media-server.com/m/p/89rbd7rh/lan/en> for the live webcast feed.

A replay of the call can be accessed on Emergent's website [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com) under "[Investors](#)."

**About Emergent BioSolutions**

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com). Follow us @emergentbiosolu.

###